BUZZ-ReNerve eyes best session on record after US nerve repair tech approval
Reuters2025-11-13
BUZZ-ReNerve eyes best session on record after US nerve repair tech approval** Shares of Australia's ReNerve RNV.AX jump as much as 109.5% to A$0.22, marking their best session on record
** Stock hits its highest since March 28
** Medical device maker's nerve repair technology - NervAlign Nerve Cuff - gains approval for use across the US Department of Defense and Veterans Affairs healthcare systems
** Co adds that it has received both an initial purchase order and a subsequent repeat order from federal medical facilities
** Session lifts RNV to the green, shares up 2.9% YTD
(Reporting by Shruti Agarwal in Bengaluru)
((Shruti.Agarwal@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
